For citations:
Markov V.A., Duplyakov D.V., Konstantinov S.L., Klein G.V., Aksentiev S.B., Platonov D.Yu., Vyshlov E.V., Ponomarev Е.A., Rabinovich R.M., Makarov E.L., Kulibaba E.V., Yunevich D.S., Kritskaya O.V., Baranov E.A., Talibov O.B., Kutsenko V.A., Orlovsky A.A., Vyazova N.L., Koledinsky A.G., Semenov A.M., Semenov M.P., Yarovaya E.B., Uskach T.M., Shakhnovich R.M., Tereshchenko S.N., Markin S.S. Advanced results of Fortelyzin® use in the FRIDOM1 study and real clinical practice. Russian Journal of Cardiology. 2022;27(8):5178. (In Russ.) https://doi.org/10.15829/1560-4071-2022-5178
Email this article 